

# Molecular genetics of schizophrenia: past, present and future

SUMAN PRASAD, PRACHI SEMWAL, SMITA DESHPANDE\*, TRIPTISH BHATIA,  
V L NIMGAONKAR\*\* and B K THELMA<sup>†</sup>

*Department of Genetics, University of Delhi South Campus, Benito Juarez Road, New Delhi 110 021, India*

*\*Department of Psychiatry, Dr Ram Manohar Lohia Hospital, New Delhi 110 001, India*

*\*\*Department of Psychiatry and Human Genetics, University of Pittsburgh School of Medicine and  
Graduate School of Public Health, Pittsburgh, PA 15213, USA*

*<sup>†</sup>Corresponding author (Fax, 91-11-6885270; Email, humgen@del3.vsnl.net.in).*

Schizophrenia is a severe neuropsychiatric disorder with a polygenic mode of inheritance which is also governed by non-genetic factors. Candidate genes identified on the basis of biochemical and pharmacological evidence are being tested for linkage and association studies. Neurotransmitters, especially dopamine and serotonin have been widely implicated in its etiology. Genome scan of all human chromosomes with closely spaced polymorphic markers is being used for linkage studies. The completion and availability of the first draft of Human Genome Sequence has provided a treasure-trove that can be utilized to gain insight into the so far inaccessible regions of the human genome. Significant technological advances for identification of single nucleotide polymorphisms (SNPs) and use of microarrays have further strengthened research methodologies for genetic analysis of complex traits. In this review, we summarize the evolution of schizophrenia genetics from the past to the present, current trends and future direction of research.

[Prasad S, Semwal P, Deshpande S, Bhatia T, Nimgaonkar V L and Thelma B K 2002 Molecular genetics of schizophrenia: past, present and future; *J. Biosci. (Suppl. 1)* 27 35–52]

## 1. Introduction

Schizophrenia is a common disorder with a proven genetic basis but complex mode of inheritance. Onset is generally during adolescence with a lifetime morbid risk being approximately 1% in the general population (American Psychiatric Association 1987). A constellation of features including hallucinations and delusions characterize schizophrenia. Notwithstanding several studies on segregation analyses, a consistent Mendelian inheritance pattern has not been observed. This failure can be attributed to both, the genetic and phenotypic heterogeneity underlying the disease. Twin and adoption studies as well as familial

clustering have supported a genetic etiology of this illness. However, absence of full concordance among monozygotic twins suggests a role for non-genetic factors in addition to the genetic component.

Till now, no susceptibility gene for schizophrenia has been detected consistently, though a large number of genes have been speculated to be associated with the disorder. A number of parametric and non-parametric linkage studies done so far have failed to pinpoint a single major gene responsible for the causation of the disease. Multiple genes conferring moderate effects have been proposed to provide susceptibility to schizophrenia (McGuffin *et al* 1995) and this is consistent with the

**Keywords.** Association strategy; candidate genes/sites; linkage analysis; neurotransmitters; schizophrenia

Abbreviations used: COMT, Catechol *o*-methyltransferase; DAT, dopamine transporter; DR, dopamine receptor; HLA, human leucocyte antigen; IDDM, insulin dependent diabetes mellitus; MAO, monoamine oxidase; MHC, major histocompatibility complex; RA, rheumatoid arthritis; RFLP, restriction fragment length polymorphism; SNPs, single nucleotide polymorphisms; TDT, transmission disequilibrium test; TH, tyrosine hydroxylase; VCFS, velocardiiofacial syndrome.

pattern of risk to the family members and epistatic model of multiple contributing loci given by Risch (1990). However, as yet there is neither a clue to the number of genes involved nor to the degree of interaction between the genes and the contribution of each gene to the overall susceptibility to this multifactorial disorder.

Lack of a consistent phenotypic, cytogenetic, or biochemical marker or a neurophysiological test or any specific features (like neurofibrillary tangles in case of Alzheimer's disease) have been a major drawback in both schizophrenia diagnosis and research. One of the most consistent phenotypic marker that has been observed is the eye movement dysfunction. Though eye movement dysfunction was observed and reported by Diefendorf and Dodge in 1908, further advances did not occur till Holzman *et al* (1973) investigated it further. Since then there have been several reports with elevated rates of eye tracking dysfunction in patients suffering from schizophrenia (reviewed by Levy *et al* 1993), and also non-psychotic first-degree relatives. Recently, Arolt *et al* (1996) defined eye tracking dysfunction as a putative phenotypic marker which mapped to a locus on chromosome 6, a region already implicated for schizophrenia, but it would be premature to draw firm conclusions unless additional replicative studies are undertaken.

## 2. History

The approach to find the putative biochemical basis in schizophrenia has been a little different from most other disorders. The fortuitous discovery of chlorpromazine, a drug to treat schizophrenia in the 1950's paved the way for such research. Chlorpromazine was found to have beneficial effect on patients with schizophrenia and its extraordinary success led to the hope of understanding biochemistry of the illness. *In vitro* studies on the brain tissues of animals conducted revealed that drugs such as chlorpromazine, haloperidol and other antipsychotic drugs effective in treatment of schizophrenia, were dopamine receptor antagonists. The clinical efficacy of these drugs was correlated with affinity for dopamine D2 receptors. This led to the development of "dopamine theory" of schizophrenia which postulated brain dopaminergic hyperactivity (Thomson 1996). However, dopamine levels or receptors have not shown to be elevated consistently in affected individuals. This aroused the interest in various other neurotransmitters and their receptors present in the brain. The dopamine theory dominated schizophrenia research for the next two decades and still continues to do so.

A large number of early studies based on segregation analyses supported a genetic etiology underlying this disease. However, it was the development of restriction

fragment length polymorphism (RFLP) as a mapping tool by Botstein *et al* (1980) which provided markers that could be used to track the chromosomal region(s) of interest. A cytogenetic marker for the probable location of a schizophrenia gene came much later in 1980's when a balanced translocation was reported in a family with two males affected with schizophrenia, an uncle and a nephew. Both the males were found to be partially trisomic for chromosome 5q11.2-q13.3 and carried an extra copy of this region translocated onto chromosome 1. This initial excitement also occurred because chromosome 5q harbours the gene for glucocorticoid receptor, and disturbances in its metabolism could induce psychotic symptoms (though subsequent studies showed the locus for this receptor to be located outside the 5q11-q13 region). Using RFLP markers, Sherrington *et al* (1988) found linkage in two British and five Icelandic families with 39 cases of schizophrenia and Kennedy *et al* (1988) provided evidence against linkage in this region in Swedish samples. Linkage to this region was also ruled out by McGuffin (1990). Subsequently, all the putative biochemical and cytogenetic markers were evaluated with fervour using linkage and association studies but none have provided consistent results.

The completion of a comprehensive genetic map of human genome using the microsatellite markers in middle of 1990's enabled genome-wide linkage analysis. With a large collection of well-documented families and densely spaced microsatellite markers, all human chromosomes were screened worldwide by independent groups or in collaborations. Many promising candidate regions have since been found and work is in progress to establish linkage or association. The late 1990's has given an additional tool in the form of SNP's, which are present abundantly in the genome and can be used in conjunction with the microsatellite markers.

## 3. Strategies for finding genes for schizophrenia

The genetic analysis of multifactorial disorders has remained a challenge due to the possible risk conferred by multiple genes of small effect, incomplete penetrance, complex and uncertain mode of inheritance along with the involvement of non-genetic factors. Currently, both association strategies with robust statistical methods as well as the linkage analyses are being used to unravel the genes for schizophrenia.

The methods to discover the genes for schizophrenia can be broadly dichotomized into parametric and non-parametric methods. (i) Parametric methods need the specification of the Mendelian mode of inheritance, number of genes involved, frequency of each susceptibility gene and their penetrance. These methods are useful

for finding the genes for rare disorders or genes of major effect. Conventional linkage analysis includes the study of segregation of marker along with the disease condition within a family and requires generally a large multi-generational and multi-member affected pedigree. However, the main disadvantage of this approach is that it cannot detect genes of small effect, a hallmark of complex traits. Moreover, the mode of inheritance, which is unclear for schizophrenia, has to be specified. (ii) Non-parametric methods appropriately termed “model free analysis” do not require any model specification. A non-parametric method has also been developed for linkage analysis where affected sib-pairs are used but the major limitation of this method is the large number of sib-pairs required for finding a gene of modest effect.

### 3.1 Association studies

Unlike linkage methods, association studies are population based and provide an alternative to linkage studies for detecting the genes of small effect. Both case-control approach and family based designs are commonly used to detect association. In contrast to the conventional case-control approach, often marred by the population stratification bias, family based designs like haplotype relative risk (HRR) and transmission disequilibrium test (TDT) are methods of choice (Ewens and Spielman 1995). TDT however, requires at least one heterozygous parent and uses information only from the informative matings and hence a large number of families are discarded from the analysis resulting in loss of power to detect putative association.

## 4. Current direction of research in schizophrenia

Current research in schizophrenia includes four directions: (i) Detection of structural abnormalities in brain, (ii) evaluation of the effect of drugs on the target receptors, neurotransmitters and the physiology of the brain, (iii) association and linkage studies with putative genes identified based on the biochemical or pharmacological evidence or candidate regions identified by the genome scan studies and (iv) role of epigenetic factors in disease causation.

Several sophisticated techniques like computed tomography (CT), magnetic resonance imaging (MRI), functional imaging and positron emission tomography (PET) along with the conventional post-mortem studies have been used to study the anatomy of the brain of affected individuals and controls. However, this aspect does not fall in the purview of this review and therefore, will not be discussed.

### 4.1 Role of neurotransmitters and drugs in the etiology of schizophrenia

Most of the therapeutic drugs used for the treatment of schizophrenia interfere with the function of neurotransmitter(s) or its receptor(s). Several key neurotransmitters especially dopamine and serotonin have thus become the focal point of schizophrenia research.

Neurotransmitters have been implicated in the etiology of schizophrenia since the time dopamine hypothesis was conceived. A large number of investigations were carried out to explain the role of dopamine, its various receptors and the genes involved in the dopamine neurotransmission pathway but none of the genes so far have been convincingly implicated in the etiology of schizophrenia. Further, it was observed that the drugs blocking dopamine receptors primarily were not effective in the treatment of all patients. Recently several drugs like clozapine (trade name Clozaril) have been marketed. These drugs appear to be as efficacious as conventional medications, with fewer side effects.

The monoaminergic group of neurotransmitters, their receptors and the genes involved in their uptake, synthesis, transport, reuptake and degradation may all play an important role in the pathogenesis of schizophrenia. Though most studies have focused on the dopaminergic and serotonergic group, role of other neurotransmitters and the genes involved in their metabolism like  $\gamma$ -aminobutyric acid (GABA) type A has also been evaluated. Briefly, the role of some of the candidate genes would be discussed.

**4.1a Dopaminergic system:** Five dopamine receptors have been identified (Grandy *et al* 1989; Dearry 1990; Giros *et al* 1990; Sunhara *et al* 1991; Van Tol *et al* 1991) so far and these can be broadly classified into 2 families: D1 and D2 (Kebabian and Calne 1979). Each of these receptors comprise of about 400 amino acids and are transmembrane protein with seven hydrophobic domains spanning the neural membrane. The structure of some of these receptors is similar to that of other G-protein coupled receptors.

- **Dopaminergic receptors**

**D1 family:** This family consists of two receptors: Dopamine receptor D1 (DRD1) and DRD5 (table 1).

**D2 family:** This family consists of three receptors: DRD2, DRD3 and DRD4 (table 1).

- **Dopamine transporter**

Beside the dopaminergic receptors, dopamine transporter (DAT) gene which is located on chromosome 5p15.3 (Vandenberg *et al* 1992a) and involved in the reuptake

**Table 1.** Genes involved in dopaminergic pathway.

Receptor	Location	Function and significance	Linkage and association studies	Result
<i>D1 family</i>				
DRD1	5q35.1	Involved in memory, emotion and cognition, the functions that are highly disturbed in schizophrenics  Several polymorphisms in 5' and 3' UTR of the gene (Grandy <i>et al</i> 1990; Litt <i>et al</i> 1991; Dollfus <i>et al</i> 1996; Kojima <i>et al</i> 1999)	Grandy <i>et al</i> 1990; Litt <i>et al</i> 1991; Nothen <i>et al</i> 1993a; Cichon <i>et al</i> 1994; Liu <i>et al</i> 1995; Kojima <i>et al</i> 1999	No significant association with any of the polymorphisms
DRD5	4p 15.3	DRD5 is neuron specific and is localized within the limbic regions of the brain  Displays high affinity for dopamine	Asherson <i>et al</i> 1998	No significant association
<i>D2 family</i>				
DRD2	11q 22-q23	Second most abundant dopamine receptor  Higher density of DRD2 in schizophrenic brains (Sedvall and Farde 1995)  Ser311/Cys311 polymorphism reported (Arinami <i>et al</i> 1994). Cys311 variant more in schizophrenics	Gejman <i>et al</i> 1994; Nanko <i>et al</i> 1994; Asherson <i>et al</i> 1994; Nothen <i>et al</i> 1994; Sobell <i>et al</i> 1994  Shaikh <i>et al</i> 1994	No significant association  Positive association
DRD3	3q13.3	Expression of DRD3 is restricted to the limbic areas of the brain, site for emotion and cognition that is highly disturbed in schizophrenics  Selective loss of DRD3 mRNA in parietal and motor regions of postmortem schizophrenic brains (Schmauss <i>et al</i> 1993)  A to G substitution polymorphism leading to creation of MscI site in exon 1 of DRD3 gene and increased homozygosity at either allele is associated with schizophrenia (Crocq <i>et al</i> 1992)	Crocq <i>et al</i> 1992; Nimgaonkar <i>et al</i> 1993; Mant <i>et al</i> 1994  Nothen <i>et al</i> 1993b; Jonsson <i>et al</i> 1993; Nanko <i>et al</i> 1993; Chen <i>et al</i> 1997a; Prasad <i>et al</i> 1999  Please see Jonsson <i>et al</i> (1999) for exhaustive reference	Significant association  No association
DRD4	11p15.5	Higher affinity than other dopamine receptors for atypical antipsychotic clozapine  Polymorphic 48 base pair repeat in putative third cytoplasmic loop	Sommer <i>et al</i> 1993	No significant association

of dopamine back in the presynaptic terminal has also been considered as a possible candidate. A 40 bp VNTR polymorphism was identified in the 3' untranslated region of this DAT gene. Alleles with 9 and 10 repeats have been observed to be predominant in most of the populations (Vandenberg *et al* 1992b; Perisco *et al* 1993; Nakatome *et al* 1996). But no significant association (Daniels *et al* 1995; Pean *et al* 1995; Perisco and Macciardi 1997) or linkage (Byerley *et al* 1993; Perisco *et al* 1995) has been detected with any of the DAT alleles. Association studies with a RFLP polymorphism due to *Taq1* restriction site in the DAT gene have also not yielded any significant results (Perisco *et al* 1995; Pean *et al* 1995).

- *Tyrosine hydroxylase*

Tyrosine hydroxylase (TH) is a rate-limiting enzyme in the dopaminergic pathway. A rare allele of a tetranucleotide repeat HUMTHO1, located in the first intron of TH is suggested to be associated with schizophrenia (Meloni *et al* 1995) but there are also several contrary reports (Burgert *et al* 1998; Jonsson *et al* 1998).

4.1b *Serotonergic system*: Serotonin is another important neurotransmitter that governs some of the behavioural aspects like sleep, moods, hallucinations and depression. Apart from the brain, serotonin is present in certain body tissues like smooth muscles and in blood platelets. Till now seven serotonin receptors have been identified: 5HT-1, 5HT-2, 5HT-3, 5HT-4, 5HT-5, 5HT-6, and 5HT-7. There is evidence that there are 5 distinct subtypes of 5HT-2 and 3 distinct subtypes of 5HT-3 (Barnes and Sharp 1999; Matsumoto and Yoshioka 2000).

Structural similarities between LSD, a potent hallucinogen and serotonin have been observed. In addition, drugs like Reserpine have been shown to reduce brain serotonin concentrations and can also be beneficial in treatment (Stahl and Wets 1987). These observations have been some of the major lines of evidence to suggest that serotonin may have an important etiological role. Arora and Meltzer (1991) reported a significant decrease in the number of 5HT<sub>2a</sub> receptors in patients with schizophrenia as compared to the controls and negated the role of neuroleptics for this difference. Hallmeyer *et al* (1992) did not find any linkage between 5HT<sub>2a</sub> gene and schizophrenia. Joyce *et al* (1993) found that serotonin receptors and its uptake sites are altered in the limbic systems of people suffering from schizophrenia.

Polymorphism has been described in several genes in the serotonergic pathway and most of these genes have been studied to detect the association with schizophrenia. These include serotonin transporter (SERT or 5-HTT),

serotonin receptors: 5-HT<sub>1A</sub> (Erdmann *et al* 1995), 5HT<sub>1d</sub> beta (Nothen *et al* 1994; Sidenberg *et al* 1993); 5-HT<sub>2A</sub> (Warren *et al* 1993), 5-HT<sub>2C</sub>, 5-HT<sub>6</sub> (Kohen *et al* 1996; Shinkai *et al* 1999), 5-HT<sub>7</sub> (Erdmann *et al* 1996). A meta analysis study by Arranz *et al* (1998) showed association of the 102-T/C polymorphism of 5-HT<sub>2A</sub> with clozapine response in extreme responders (table 2).

4.1c *Genes involved in the degradation of monoaminergic neurotransmitters*: Monoamine oxidase (MAO) and catechol *o*-methyltransferase (COMT) are two important enzymes that are involved in the catabolism of the neurotransmitters.

MAO is present at both pre-synaptic terminal and post-synaptic cell and breaks down excess dopamine and serotonin. COMT is another inactivating enzyme present in postsynaptic cells of dopamine or NE synapse but not serotonin. Floderus *et al* (1981) reported a higher COMT activity in schizophrenics which has not been replicated in many subsequent studies. COMT gene has been mapped to chromosome 22q11.2 and microdeletions in this region leading to a number of diseases including the velocardiofacial syndrome (VCFS) encompass the COMT locus (Dunham *et al* 1992). Further, Pulver *et al* (1994) have reported VCFS patients to have a high risk for developing schizophrenia.

#### 4.2 Association and linkage studies with putative genes and candidate regions

A large number of putative genes chosen on the basis of biochemical and pharmacological evidence and candidate sites identified using genome scans have been tested for association or linkage with schizophrenia. Table 3 lists the location of some important putative genes and chromosome sites based on some of the important linkage/association studies undertaken for schizophrenia. Figure 1 is a graphical presentation of their distribution on different chromosomes.

#### 4.3 Role of epigenetic factors in disease causation

Epigenetics is a branch of developmental biology that investigates the mechanism by which heritable changes in gene expression occur without the change in the genetic material. Epigenetic phenomenon has been observed in many organisms and it includes position effect variegation, paramutation, age dependent DNA modification etc. (Bestor *et al* 1994; Petronis *et al* 1999). The epigenetic factors may show only partial stability (metastability) when transmitted from one generation to the next generation (Petronis *et al* 1999). New lines of investigations suggest that epigenetic mechanisms might play

an important role in the etiology of complex traits like schizophrenia. Various epigenetic factors like DNA methylation and interaction(s) among gene products might complement the genetic component (Holliday 1989). However, the role of epigenetics in disease causation has not been investigated intensively at present.

Environmental factors can also cause epigenetic changes in the DNA that can result in altered gene expression leading to disease manifestation. Recent studies are suggestive of the role of viruses in the development of schizophrenia. Neurodevelopmental defects have been seen frequently in children of women encountering viral exposure during pregnancy. This theory is also supported by the fact that viral infections like influenza, measles etc. are more frequent during winter months and several studies indicate that children born during winter months develop schizophrenia more often than others (Battle *et al* 1999). It has been speculated that neurodevelopmental defects occur when a mother contracts a viral infection early during pregnancy. Various viruses like influenza (Crow 1997), borna (Iwahashi *et al* 1998), herpes (DeLisi *et al* 1986) etc. have thus been investigated in schizophrenics.

Retroposons have also been advocated for causation of schizophrenia (O'Reily and Singh 1996; Yolken *et al* 2000). Various endogenous retroposon like sequences are present in the genome which remain latent until some trigger such as an infection from other viruses, hormones or chemical messengers released by immune system trigger them into action resulting in the development of the disease (Yolken *et al* 2000).

Four important theories of schizophrenia have been discussed from an epigenetic point of view in a review by Petronis *et al* (1999) with an intent to answer some very basic aspects of schizophrenia genetics. These hypotheses encompass 'neurodevelopmental hypothesis', 'dopamine dysregulation hypothesis', 'viral hypothesis' and 'genetic anticipation and the unstable DNA hypothesis'. DNA methylation occurring during meiosis, gametogenesis etc. has been suggested to have the potential to cause subtle changes in brain development, resulting in neurodevelopmental defects (Petronis *et al* 1999). Dopamine dysregulation has been correlated to control of DRD2 expression, which is believed to be due to differential methylation patterns. In addition, integration of viruses at

**Table 2.** Genes involved in serotonergic pathway.

Receptor	Location	Function and significance	Linkage and association studies	Result
5HT2A gene	13q14	Binds clozapine (antipsychotic) more effectively than dopamine  Both gene and promoter have been investigated.  Gene polymorphism: T to C polymorphism viz. T102C (Warren <i>et al</i> 1993; Inayama <i>et al</i> 1994)	Williams <i>et al</i> 1996, 1997; Spurlock <i>et al</i> 1998  Nimgaonkar <i>et al</i> 1996; Chen <i>et al</i> 1997b; Hawi <i>et al</i> 1997; Verga <i>et al</i> 1997; He <i>et al</i> 1999; Lin <i>et al</i> 1999	Significant association  No significant association
5HT2A promoter	Chromosome 13	Regulatory region of 5HT2A gene and thus mutations in this region can influence the 5HT2a gene expression and its density  A to G polymorphism at position - 1438 (Spurlock <i>et al</i> 1998)	Spurlock <i>et al</i> 1998; Kouzmenko <i>et al</i> 1999	No significant association
SERT or 5HTT	17q11.2-q12	VNTR in intron 2  44 base pair deletion/insertion in the 5HTT promoter region resulting in long and short variant  Short variant leads to reduced 5HTT expression (Heils <i>et al</i> 1996)	Heils <i>et al</i> 1996; Hranilovic <i>et al</i> 2000  Brilhault <i>et al</i> 1997  Naylor <i>et al</i> 1998; Oliveira <i>et al</i> 1998; Rao <i>et al</i> 1998	Significant Association  No significant association
TPH gene	Chromosome 11	Rate limiting enzyme in the synthesis of serotonin  Polymorphic site resulting in U and L allele in the intron	Serretti <i>et al</i> 1999	No significant association
TPH promoter	Chromosome 11	A to G transition at position 6526	Rotando <i>et al</i> 1999	No significant association

**Table 3.** Notable putative genes and chromosomal regions studied for schizophrenia gene using linkage and association strategies.

Chromosome No.	Chromosomal region	Significance	Linkage/association studies
1	1p 35-32 1q 42-1 (1q44) 1q 21-3	* Translocation * hSKCa3 gene	Garver <i>et al</i> (1998) St. Clair <i>et al</i> (1990) Blouin <i>et al</i> (1998) Wittekindt <i>et al</i> (1998)
2	(2p15-14) 2q21	* Balanced translocation	Shaw <i>et al</i> (1998) Maziade <i>et al</i> (1993)
3	3p 24 3q 13-3	* Dopamine receptor D3 gene	Pulver <i>et al</i> (1995) Crocq <i>et al</i> (1992); see Jonsson <i>et al</i> (1999) for exhaustive reference
4	4p 4q 24-32	* *	Asherson <i>et al</i> (1998) Kaufmann <i>et al</i> (1998); Kennedy <i>et al</i> (1998); Hovatta <i>et al</i> (1999)
5	5p14-1-13-11 5q 5q21-23	* * *	Silvermann <i>et al</i> (1996) Sherrington <i>et al</i> (1988) Straub <i>et al</i> (1997)
6	6p24-22  6q 21-22-3	* HLA genes Eye tracking dysfunction gene *	Moises <i>et al</i> (1995); Straub <i>et al</i> (1995) Nimgaonkar <i>et al</i> (1992, 1995, 1997); Wright <i>et al</i> (1996); summarized in Gibson <i>et al</i> (1999) Arolt <i>et al</i> (1996) Cao <i>et al</i> (1997)
7	7q21-1-q21-3	*	Blouin <i>et al</i> (1998)
8	8p22-21	*	Pulver <i>et al</i> (1995); Kendler <i>et al</i> (1996)
9	9q34-3	* Dopamine <i>b</i> hydroxylase gene A subunit of NMDA receptor gene	Riley <i>et al</i> (1997) Meszaros <i>et al</i> (1996) Heresco <i>et al</i> (1999)
10	10p15-q21	*	Faraone <i>et al</i> (1998); Schwab <i>et al</i> (1998); Foroud <i>et al</i> (2000)
11	11p15-5 11q 22-23  11q	Dopamine D4 receptor gene Dopamine D2 receptor gene Translocation	Sommer <i>et al</i> (1993) Gejman <i>et al</i> (1994); Shaikh <i>et al</i> (1994); reviewed in Gill <i>et al</i> (1993) St. Clair <i>et al</i> (1990)
12	–	*	Dawson <i>et al</i> (1995)
13	13q14 13q14-1-q32 13q32	5HTR2a (serotonin receptor 2a) * *	Campbell <i>et al</i> (1997); Erdmann <i>et al</i> (1996) Riley <i>et al</i> (1998) Blouin <i>et al</i> (1998); summarized in Barden and Morissette (1999)
14	–	*	Craddock and Lendon (1999)
15	15q13-q14	* <i>a</i> 7 nicotinic cholinergic receptor subunit gene (CHRNA7)	Curtis <i>et al</i> (1999) de Leon <i>et al</i> (1995); summarized in Riley and McGuffin (2000)
16	–	*	Detera-Wadleigh (1999)

Contd . . .

(Table 3. *Contd.*)

Chromosome No.	Chromosomal region	Significance	Linkage/association studies
17	17q11.2-q12	Serotonin transporter gene (5HTT)	Heils <i>et al</i> (1996); Rao <i>et al</i> (1998)
18	18p	*	Schwab <i>et al</i> (1998); Calzolari <i>et al</i> (1996)
	18q21.1	*	Williams <i>et al</i> (1999); summarized in Riley and McGuffin (2000)
19	–	*	Parfitt <i>et al</i> (1996); reviewed in Gejman (1999)
20	20p		Hovatta <i>et al</i> (1998)
21	–	*	Byerley <i>et al</i> (1995); reviewed in Gurling (1998)
22	22q13	IL2RB gene	Pulver <i>et al</i> (1994)
		COMT gene (catechol-o-methyl transferase)	Chen <i>et al</i> (1999)
		14-3-3 protein <i>h</i> -chain gene (YWHAH)	Toyooka <i>et al</i> (1999)
	22q11	Deletion in this region	Basset <i>et al</i> (1998); Basset and Chow (1999); Murphy <i>et al</i> (1998)
	22q12-q13	*	Pulver <i>et al</i> (1994)
	22q (D22S278)	*	Moises <i>et al</i> (1995); summarized in Riley and McGuffin (2000)
X	Pseudoautosomal locus	*	Maier <i>et al</i> (1995); d'Amato (1994)
	Xp11	*	Dann <i>et al</i> (1997)
	Xq27-28	*	DeLisi (1997); summarized in Riley and McGuffin (2000)
Y	Pseudoautosomal region	*	Yamada <i>et al</i> (1982); Crow (1992); summarized in DeLisi (1997)

\*Indicates candidate regions identified by genome scan studies.

specific positions and their activity is advocated to be under control of epigenetic mechanisms, leading to disruption of neurodevelopmental processes by viral toxic substances, resulting in brain abnormalities associated with schizophrenia. Epigenetic mechanisms have also been suggested to be the molecular equivalents or a cause of anticipation by Petronis *et al* (1999). Subsequently, Petronis (2000) has affirmed the role of genomic imprinting and differential methylation of regulatory regions as epigenetic factors in regulation of Serotonin 2A receptor gene (HTR2A) as well.

Besides neurotransmitter disturbances, immune dysfunction has also been observed in a subset of schizophrenics. Various markers from immune system have thus been studied. A large number of reports indicate that schizophrenia like most other neurological disorders shows phenomenon of anticipation. These two aspects are briefly discussed below.

### 5. Immune response in schizophrenics

A large number of inherited biochemical markers have been studied for association with schizophrenia including

the immunoglobulins, haptoglobin types, blood groups, substance P, enzymes like porphobilinogen deaminase, adenosine deaminase, tyrosine hydroxylase etc. (summarized in Nimgaonkar *et al* 1992). None of the markers have shown a consistent association. However, an increasing number of studies have suggested occurrence of immune dysfunction in a subset of schizophrenics.


Altered levels and numbers of various components of immune system like immunoglobulins, complements, interleukins (IL2), CD3<sup>+</sup> and CD4<sup>+</sup> have been reported (Solomon 1981; DeLisi *et al* 1982; Ganguli and Rabin 1989; Muller *et al* 1991; Zamani *et al* 1994). Since the HLA system governs the immune responses, HLA genes were implicated in the etiology of schizophrenia. Past association studies with various HLA class I alleles yielded inconsistent results (summarized in Nimgaonkar *et al* 1992) except HLA-A9. The reason suggested for inconsistencies include population stratification, case-control mismatch, different diagnostic criteria and use of serological techniques which are error prone (Nimgaonkar *et al* 1992). It has been further observed that HLA class II alleles might be more important than HLA class I alleles in view of the autoimmune pathology suggested for schizophrenia.

Autoimmune pathology has been advocated (Knight 1982; Ganguli and Rabin 1987) because of increased levels of antibrain antibodies (Heath and Krupp 1967; Shima *et al* 1991). Also, an inverse relationship between schizophrenia and autoimmune diseases like rheumatoid arthritis (RA) (Eaton *et al* 1992; Wright *et al* 1996) and insulin dependent diabetes mellitus (IDDM) (Finney 1989) has been reported.

Human leucocyte antigen (HLA) class II alleles play an important role in autoimmune responses (Trucco 1992; Lechler 1994) and many autoimmune diseases seem to be HLA DR and DQ associated (Mignot *et al* 1995). Several studies have reported linkage with schizophrenia around the HLA locus (Moises *et al* 1995; Schwab *et al* 1995).

Since RA and IDDM are inversely related to schizophrenia, HLADRB1\*04 (DR4) and HLADQB1 region positively associated with RA and IDDM respectively, were studied (Finney 1989; Knight *et al* 1992). A negative association of schizophrenia with DR4 (Wright *et al* 1996) and HLADQB1\*0602 (Nimgaonkar *et al* 1992, 1995, 1997) was found. However, Gibson *et al* (1999) in their population did not find any association of schizophrenia with A9, DR4 or DQB1\*0602.

Recently Wei and Hemmings (2000) reported that the HSMHC3A5 locus present near the major histocompatibility complex (MHC) class I and class II junction is significantly associated with schizophrenia. This locus harbours the Notch 4 gene, which consists of 30 exons



**Figure 1.** A glimpse of genes/chromosomal sites implicated for schizophrenia based on linkage and association studies. Black circle denotes centromere. Red colour denotes candidate sites/location of candidate genes.

and spans 36.8 kb region inclusive of a putative promoter. Haplotype combination of markers especially SNP2-(CTG)<sub>n</sub> from Notch 4 locus showed strong association with schizophrenia. The function of Notch 4 is not known in humans but animal studies have shown that it is involved in neurodevelopmental process. Thus, non-immune related genes localized to the HLA region may have an etiological role in schizophrenia.

## 6. Anticipation in schizophrenia

Dynamic mutations characterized by expansion of triplet repeats are known to cause at least 13 different neurodegenerative disorders. Genetic anticipation, a phenomenon characterized by increase in disease severity combined with an early onset of disease with succeeding generations, has been observed in several neuropsychiatric disorders with trinucleotide expansions (Ross 1993; Johnson *et al* 1997) and suggested in schizophrenia as well (Bassett and Honer 1994). Various trinucleotide repeats have been studied using candidate gene as well as the repeat expansion detection (RED) technique (Rubinsztein *et al* 1994; Jain *et al* 1996; McInnis *et al* 1996; Gaitonde *et al* 1997; Saleem *et al* 1998). Large CAG repeats have been reported to be more frequent in patients than in controls (Morris *et al* 1995; O'Donovan *et al* 1995). Therefore, genes with unstable trinucleotide repeats are being considered as suitable candidates for underlying pathology of schizophrenia and are being analysed.

Chandy *et al* (1998) described one such candidate gene which is a human calcium-activated potassium channel gene (hSKCa3), and has been mapped to 1q21.3. This gene at the N-terminal region contains two contiguous CAG repeats with the second repeat being polymorphic (repeat size varying from 12 to 28 repeats). The long allelic variant of the polymorphic repeat is shown to be overrepresented in the schizophrenics in comparison to controls (McInnis *et al* 1998). However, most of the reports have been controversial (Bowen *et al* 1998; Austin *et al* 1999; Guy *et al* 1999; Antonarkis *et al* 1999; Joobar *et al* 1999; Saleem *et al* 2000a).

Several other ion-channels like  $\gamma$ -aminobutyric acid (GABA), N-methyl-D-aspartate (NMDA) receptor and its ligand (e.g. AMPA) are also being investigated since antagonists to these receptors produce schizophrenic symptoms (Tsai *et al* 1998; Gargus *et al* 1998; Aghajanian and Marek 2000).

## 7. Schizophrenia research in India

A large number of studies for schizophrenia have been conducted mainly in the Caucasoid population. However, it is desirable to perform similar studies in different ethnic groups to reaffirm the status of the association or

linkage identified. Indian population is very well suited for such studies as it satisfies many criteria required for the investigation of complex traits. Besides, Indian population is an attractive large reservoir of samples both due to its population size as well as the high rate of marital stability, the latter essential for family based analysis.

Work on schizophrenia genetics has been initiated since the last 5–6 years by two major groups, one of the authors and the other one based at NIMHANS in Bangalore. The Hindi version of the Diagnostic Interview for Genetic Studies (DIGS) and Family Interview for Genetic studies (FIGS) (Deshpande *et al* 1998) has been validated and is being used by the authors group. A total of 260 families including sib-pairs and trios have been collected and used for genetic analysis. Genes in the dopaminergic and serotonergic pathways in the brain have been studied in predominantly North Indian samples by the authors. Using family based association test, DRD3 locus did not show any association (Prasad *et al* 1999). In another study, four genes (5HT2A, TPH, COMT and DAT) involved in monoaminergic pathway evaluated using TDT, have also failed to show any significant association (Semwal *et al* 2001). An association between cytosolic phospholipase A2 (cPLA2) locus and schizophrenia has also been evaluated in the family based samples among Indians but no significant association has been detected (Chowdari *et al* 2001). A large difference in CAG repeat allele sizes in case of patients suffering from schizophrenia compared to the controls has been reported at the Machado-Joseph Disease (MJD) locus. Though longer CAG repeat at MJD locus is not associated with schizophrenia, the role of smaller unstable repeats in disease manifestation cannot be excluded (Saleem *et al* 1998). Saleem *et al* (2000a) observed no association with serotonin transporter (5-HT) in patients suffering from bipolar disorder based on case-control approach. Though no association has been observed with the hSKCa3 polymorphism by the same group (Saleem *et al* 2000b) they have shown that a large difference in allele sizes greater than or equal to five occurs in patients compared to controls. Association studies with candidate genes that may play a role in susceptibility to Tardive Dyskinesia among schizophrenia patients is being investigated by the author's group. This is expected to serve as a model for pharmacogenetic studies especially of complex traits. Presently, the author's group is carrying out high throughput SNP genotyping of several candidate genes in schizophrenia.

## 8. Future strategies

Considering the complex nature of the common disorders, with no clue to the number and nature of genes involved

or their location, it is difficult to search for the genes using the conventional techniques that help unravel the genes for single gene disorders. Various new experimental and statistical methodologies have been developed and are in current use to hunt for the genes underlying schizophrenia.

Non-parametric method of linkage analysis using large collection of affected sib-pairs along with the genome scan studies using affected sib-pairs would be a more effective and favoured strategy to track genes of minor effect. Considering schizophrenia is a polygenic disorder, gene-gene interaction among putative markers is expected to yield important clues to the underlying pathology. Haplotype analysis could be informative where genotypic combination might be crucial in providing the susceptibility. Along with the exons of candidate genes, intron sequences should also be searched for mutations. SNPs coupled with the powerful technique of DNA microarrays can add a new dimension to the existing research methodologies. Strategies employed in parallel studies on other complex traits such as diabetes and hypertension would also be useful in navigating the search for genes. Type I diabetes exemplifies the role of non-parametric linkage and association mapping in identifying the susceptibility genes and loci. Initially, case-control association studies revealed association of type I diabetes to HLA at 6p21 and the insulin gene on 11p15 chromosomal region (reviewed by Thomson *et al* 1989). Using affected sib-pairs, linkage was subsequently demonstrated to HLA (IDDM1) (Cudworth and Woodrow 1975) and non-HLA genes like IDDM4 (11q13), IDDM5 (6q25), and IDDM12 (2q33) while other non-HLA genes like IDDM2 were identified using association studies (reviewed by Thomson 2001). In hypertension, on the other hand, SNP identification in candidate genes is already underway in search for common variants that might provide susceptibility. Around 874 SNPs in 75 candidate genes for hypertension have been identified by Halushka *et al* 1999 (see review by Gray *et al* 2000).

Association studies, but with more powerful analytical tools such as SNPs, would remain instrumental in searching the genes for common disorders because of their significant power to identify the pathogenic allele(s) in contrast to the linkage strategy. Limitation of small sample size in such studies could be overcome by meta-analysis approach. The meta-analysis method synthesizes information by pooling relatively weak signals from independent genetic association studies into consolidated stronger evidence for genetic effects. Thus, evidence from multiple studies are pooled and variations among studies are accounted for, to arrive at a pooled measure of genetic linkage (Gu *et al* 2001). However, the limitation in performing association studies would still be the requirement of prior knowledge about the candidate

genes/candidate chromosomal sites. Therefore, availability of extensive data on polymorphism in the whole genome could provide a large number of markers for effective association studies. SNPs coupled with microsatellite markers seem to be the ideal tools for such studies and use of microarrays could provide a high-throughput genotyping method in the near future.

## References

- Aghajanian G K and Marek G J 2000 Serotonin model of schizophrenia: emerging role of glutamate mechanisms; *Brain Res. Brain Res. Rev.* **31** 302–312
- American Psychiatric Association 1987 *Diagnostic and Statistical Manual* Revised 3rd edition (Washington DC: American Psychiatric Association)
- Antonarakis S E, Blouin J L, Lasseter V K, Gehrig C, Radhakrishna U, Nestadt G, Housman D E, Kazazian H H, Kalman K, Gutman G A, Fantino E, Chandy K G, Gargus J J and Pulver A E 1999 Lack of linkage or association between schizophrenia and the polymorphic trinucleotide repeat within the KCNN3 gene on chromosome 1q21; *Am. J. Med. Genet.* **88** 348–351
- Arolt V, Lencer R, Achim N, Muller-Myhsok B, Purmann S, Schurmann M, Leutelt J, Pinnow M and Schwinger E 1996 Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease; *Am. J. Med. Genet. Neuropsychiatric Genet.* **67** 560–563
- Arora R C and Meltzer H Y 1991 Serotonin<sub>2</sub> (5HT<sub>2</sub>) receptor binding in the frontal cortex of schizophrenic patients; *J. Neural. Trans.* **85** 19–29
- Arranz M J, Munro J, Sham P, Kirov G, Murray R M, Collier D A and Kerwin R W 1998 Meta-analysis of studies on genetic variation in 5-HT<sub>2A</sub> receptors and clozapine response; *Schizophr. Res.* **32** 93–99
- Asherson P, Mant R, Williams N, Cardno A, Jones L, Murphy K, Collier D A, Nanko S, Craddock N, Morris S, Muir W, Blackwood, McGuffin P and Owen M J 1998 A study of chromosome 4p markers and dopamine D<sub>5</sub> receptor gene in schizophrenia and bipolar disorder; *Mol. Psychiatry* **3** 310–320
- Asherson P, Williams N, Roberts E, McGuffin M and Owen M 1994 DRD2 Ser311/Cys311 polymorphism in schizophrenia; *Lancet* **343** 1045
- Austin C P, Holder D J, Ma L, Mixson L A, Caskey C T 1999 Mapping of hKCa3 to chromosome 1q21 and investigation of linkage of CAG repeat polymorphism to schizophrenia; *Mol. Psychiatry* **4** 261–266
- Barden N and Morissette J 1999 Chromosome 13 workshop report; *Am. J. Med. Genet.* **88** 260–262
- Barnes N M and Sharp T 1999 A review of central 5-HT receptors and their function; *Neuropharmacology* **38** 1083–1152
- Basset A S and Chow E W 1999 22q11 deletion syndrome: a genetic subtype of schizophrenia; *Biol. Psychiatry* **46** 882–891
- Basset A S, Hodgkinson K, Chow E W, Correia S, Scutt L E and Weksberg R 1998 22q11 deletion syndrome in adults with schizophrenia; *Am. J. Med. Genet.* **81** 328–337

- Basset A S and Honer W G 1994 Evidence for anticipation in schizophrenia; *Am. J. Hum. Genet.* **54** 864–870
- Battle Y L, Martin B C, Dorfman J H and Miller L S 1999 Seasonality and infectious disease in schizophrenia: the birth hypothesis revisited; *J. Psychiatr. Res.* **33** 501–509
- Bestor T H, Chandler V L and Feinberg A P 1994 Epigenetic effects in eukaryotic gene expression; *Dev. Genet.* **15** 458–462
- Blouin J L, Dombroski B A, Nath S, Lasseter V K, Wolyniec P S, Nestadt G, Thornquist M, Ulrich G, McGrath J A, Kasch L, Lamacz M, Thomas M G, Gehrig C, Radhakrishna U, Snyder S E, Balk K G, Neufeld K, Swartz K L, DeMarchi N, Papdimitriou G N, Dikeos D G, Stefanis C N, Chakravarti A, Childs B, Housman D E, Kazazian H, Antonarakis S E and Pulver A E 1998 Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21; *Nature Genet.* **10** 70–73
- Botstein D, White R L, Skolnick M H and Davis R W 1980 Construction of a genetic linkage map in man using restriction fragment length polymorphisms (RFLPs); *Am. J. Hum. Genet.* **32** 314–331
- Bowen T, Guy C A, Craddock N, Cardno A, Williams N, Spurlock G, Murphy K C, Jones L, Gray M, 1998 Replication of association between a polymorphic CAG repeat in the hSKCa3 genes and schizophrenia; *Mol. Psychiatry* **3** 32–37
- Brilhault B F, Laurent C, Thibaut F, Champion D, Chavand O, Samolyk D, Martinez M, Petit M and Mallet J 1997 Serotonin transporter gene polymorphism and schizophrenia: an association study; *Biol. Psychiatry* **42** 634–636
- Burgert E, Crocq M A, Bausch E, Macher J P and Morris-Rosendahl D J 1998 No association between the tyrosine hydroxylase microsatellite marker HUMTHO1 and schizophrenia or bipolar I disorder; *Psychiatr. Genet.* **8** 45–48
- Byerley W F, Coon H, Hoff M, Holik J, Waldo M, Freedman R, Caron M G and Giros B 1993 Human dopamine transporter gene not linked to schizophrenia in multigenerational pedigrees; *Hum. Hered.* **43** 319–322
- Byerley W, Hoff M, Holik J, Myles-Worsley M, Waldo M, Freedman R and Coon H 1995 Linkage analysis between schizophrenia and index simple-sequence repeat loci for chromosome 21; *Hum. Hered.* **45** 49–52
- Calzolari E, Aiello V, Palazzi P, Sensi A, Calzolari S, Orrico D, Calliari L, Holler H, Marzi C, Belli S, Bernardi F and Patracchini P 1996 Psychiatric disorder in a familial 15;18 translocation and sublocalization of myelin basic protein of 18q22.3; *Am. J. Med. Genet.* **67** 154–161
- Campbell D A, Sundaramurthy D, Markham A F and Pieri L F 1997 Fine mapping of the human 5-HTR2a gene to chromosome 13q14 and identification of two highly polymorphic linked markers suitable for association studies in psychiatric disorders; *Genet. Test* **1** 297–299
- Cao Q, Martinez M, Zhang J, Sanders A R, Badner J A, Cravchik A, Markey C J, Beshah E, Guroff J J, Maxwell M E, Kazuba D M, Whiten R, Goldin L R, Gershon E S and Gejman P V 1997 Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees; *Genomics* **43** 1–8
- Chandy K G, Fantino E, Kalman K, Tong L L, Ho T H, Gutman G A, Crocq M A, Ganguli R, Nimgaonkar V L, Morris-Rosendahl and Gargus J J 1998 Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder?; *Mol. Psychiatry* **3** 32–37
- Chen C-H, Liu M-Y, Wei F-C, Koong F-J, Hwu H-G and Hsiao K-J 1997a Further evidence of no association between Ser9Gly polymorphism of dopamine D3 receptor gene; *Am. J. Med. Genet.* **74** 40–43
- Chen C H, Lee Y R, Wei F C, Koong F J, Hwu H G and Hsiao K J 1997b Lack of association between 102T/C polymorphism of serotonin receptor type 2A gene and schizophrenia in Chinese; *Psychiatr. Genet.* **7** 35–38
- Chen C H, Lee Y R, Chung M Y, Wei F C, Koong F J, Shaw C K, Yeh J I and Hsiao K J 1999 Systematic mutation analysis of the catechol-O-methyltransferase gene as a candidate gene for schizophrenia; *Am. J. Psychiatry* **156** 1273–1275
- Chowdari K V, Brandstaetter B, Semwal P, Bhatia T, Deshpande S, Reddy R, Wood J, Weinberg C R, Thelma B K and Nimgaonkar V L 2001 Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family based samples; *Psychiatr Genet.* (in press)
- Cichon S, Nothen M M, Erdmann J and Propping P 1994 Detection of four polymorphic sites in the human D1receptor gene (DRD1); *Hum. Mol. Genet.* **3** 209
- Craddock N and Lendon C 1999 Chromosome Workshop: chromosomes 11, 14 and 15; *Am. J. Med. Genet.* **88** 244–254
- Crocq M-A, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz J C, Gill M, Macher J P, McGuffin P and Owen M J 1992 Association between schizophrenia and homozygosity at the dopamine D3 receptor gene; *J. Med. Genet.* **29** 858–860
- Crow T J 1992 X-Y linkage and schizophrenia; *Br. Med. J.* **305** 958
- Crow T J 1997 Influenza and schizophrenia; *Br. J. Psychiatry* **171** 91
- Cudworth A G and Woodrow J C 1975 Evidence for HLA-linked genes in “juvenile” diabetes mellitus; *Br. Med. J.* **3** 133–135
- Curtis L, Blouin J L, Radhakrishna U, Gehrig C, Lasseter V K, Wolyniec P, Nestadt G, Dombroski B, Kazazian H H, Pulver A E, Housman D, Bertrand D and Antonarakis S E 1999 No evidence for linkage between schizophrenia and markers at chromosome 15q13–14; *Am. J. Med. Genet.* **88** 109–112
- d’Amato T, Waksman G, Martinez M, Laurent C, Gorwood P, Campion D, Jay M, Petit C, Savoye C, Bastard C, Babron M C, Clerget-Darpoux F and Mallet J 1994 Pseudoautosomal region in schizophrenia: linkage analysis of seven loci by sib-pair and lob score methods; *Psychiatry Res.* **52** 135–147
- Daniels J, Williams J, Asherson P, McGuffin P and Owen M 1995 No association between schizophrenia and polymorphisms within the genes for Debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter; *Am. J. Med. Genet.* **60** 85–87
- Dann J, DeLisi L E, Devoto M, Laval S, Shields G, Smith A, Loftus J, Peterson P, Vita A, Comazzi M, Morganti C, Levinson D F, Wildenauer D, Nancarrow D J, Mowry B J, Collier D, Aranz M J, Okoro C, Owen M, Crowe R R, Andreasen N C, Silverman J M, Mohs R C, Walters M K, Lennon, D F, Hayward N K, Maier W, Albus M, Lerer B and Crow T J 1997 A linkage study of schizophrenia to markers within Xp11 near the MAOB gene; *Psychiatry Res.* **70** 131–143
- Dawson E, Powell J F, Sham P, Shaikh S, Taylor C, Clements A, Asherson P, Sargeant M, Collier D, Nanko S, Wahley S, Murray R M, McGuffin P and Gill M 1995 Systematic search for major genes in schizophrenia: methodological issues and results from chromosome 12; *Am. J. Med. Genet. Neuropsychiatric Genet.* **60** 424–433

- Dearry A, Gingrich J A, Falardeau P, Fremeau R T, Bates M D and Caron M G 1990 Molecular cloning and expression of the gene for a human D1 dopamine receptor; *Nature (London)* **347** 72–75
- de Leon J, Dadvand M, Canuso C, White A O, Stanilla J K and Simpson G M 1995 Schizophrenia and smoking: an epidemiological survey in a state hospital; *Am. J. Psychiatry* **152** 453–455
- DeLisi L E 1997 The genetics of schizophrenia: past, present and future concepts; *Schizophr. Res.* **28** 163–175
- DeLisi L E, Goodman S, Neckers L M and Wyatt R J 1982 An analysis of lymphocyte subpopulation in schizophrenic patients; *Biol. Psychiatry* **17** 1003–1009
- DeLisi L E, Smith S B, Hamovit J R, Maxwell M E, Goldin L R, Dingman C W and Gershon E S 1986 Herpes simplex virus, cytomegalovirus and Epstein-Barr antibody titres in sera from schizophrenic patients; *Psychol. Med.* **16** 757–763
- Deshpande S N, Mathur M N, Das S K, Bhatia T, Sharma S and Nimgaonkar V L 1998 A hindi version of the diagnostic interview for genetic studies; *Sch. Bull.* **24** 489–493
- Detera-Wadleigh S D 1999 Chromosome 12 and 16 workshop; *Am. J. Med. Genet.* **88** 256–259
- Diefendorf A R and Dodge R 1908 An experimental study of the ocular reactions of the photographic records; *Brain* **31** 451–489
- Dollfus S, Campion D, Vasse T, Preterre P, Laurent C, d'Amato T, Thibaut F, Mallet J and Petit M 1996 Association study between dopamine D1, D2, D3, and D4 receptor genes and schizophrenia defined by several diagnostic systems; *Biol. Psychiatry* **40** 419–421
- Dunham I, Collins J, Wadey R and Scambler P 1992 Possible role for COMT in psychosis associated with velo-cardio-facial syndrome; *Lancet* **340** 1361–1362
- Eaton W W, Hayward C and Ram R 1992 Schizophrenia and rheumatoid arthritis: A review; *Schiz. Res.* **6** 182–192
- Erdmann J, Shimron-Abarbanell D, Cichon S, Albus M, Maier W, Litchermann D, Minges J, Franzek E, Ertl M A, Heberbrand J, Remschmidt H, Lehmkuhl G, Poustka F, Schmidt M, Fimmers R, Körner J, Rietschel M, Propping P and Nöthen M M 1995 Systematic screening for mutations in the promoter and the coding region of the 5HT 1A gene; *Am. J. Med. Genet. Neuropsychiatric Genet.* **60** 393–399
- Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J, Bondy B, Chen K, Shih J C, Knapp M, Propping P and Nothen M M 1996 Systematic screening for mutations in the human serotonin-2A (5HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia; *Hum. Genet.* **97** 614–619
- Ewens W J and Spielman S 1995 The transmission/disequilibrium test: history, subdivision, and admixture; *Am. J. Hum. Genet.* **57** 455–464
- Faraone S V, Matise T, Svrakie D, Pepple J, Malaspina D, Suarez B, Hampe C, Zambuto C T, Schmitt K, Meyer J, Markel P, Lee H, Harkavy Friedman J, Kaufmann C, Cloninger C R and Tsuang M T 1998 Genome scan of European-American schizophrenia pedigrees: results of the NIMH genetics initiative and millennium consortium; *Am. J. Med. Genet.* **81** 200–295
- Finney G H 1989 Juvenile onset diabetes and schizophrenia?; *Lancet* **2** 1214–1215
- Floderus Y, Book J A and Wetterberg L 1981 Erythrocyte catechol-o-methyltransferase activity in related families with schizophrenia; *Clin. Genet.* **19** 386–389
- Foroud T, Castelluccio P F, Koller D L, Edenberg H J, Miller M, Bowman E, Rau N L, Smiley C, Rice J P, Goate A, Armstrong C, Bierut L J, Reich T, Detera-Wadleigh S D, Goldin L R, Badner J A, Guroff J J, Gershon E S, McMahon F J, Simpson S, MacKinnon D, McInnis M, Stine O C, DePaulo J R, Blehar M C and Nurnberger J I Jr 2000 Suggestive evidence of a locus on chromosome 10p using the NIMH genetics initiative bipolar affective disorder pedigrees; *Am. J. Med. Genet.* **96** 18–23
- Gaitonde E J, Sivagnanasundaram S, Morris A G, McKenna P J, Mollon J D and Hunt D M 1997 The number of triplet repeats in five brain-expressed loci with CAG repeats is not associated with schizophrenia; *Schiz. Res.* **25** 111–116
- Ganguli R and Rabin S 1989 Increased serum interleukin-2-receptor concentration in schizophrenic and brain damaged subjects; *Arch. Gen. Psychiatry* **46** 292
- Ganguli R, Rabin B S, Kelly R H, Lyte M and Raghu U 1987 Clinical and laboratory evidence of autoimmunity in acute schizophrenia; *Ann. NY Acad. Sci. USA* **496** 676–685
- Gargus J J, Fantino E and Gutman G A 1998 A piece in the puzzle: an ion channel candidate gene for schizophrenia; *Mol. Med. Today* **4** 518–524
- Garver D L, Barnes R, Holcombe J *et al* 1998 Genome wide scan and schizophrenia in African Americans; *Am. J. Med. Genet.* **81** 454–455
- Gejman P V 1999 Chromosomes 19 and 20 report; *Am. J. Med. Genet.* **88** 271
- Gejman P V, Ham A, Gelernter J, Friedman E, Cao Q, Pickar D, Blum K, Noble E P, Kranzler H R, O'Malley S, Hamer D H, Whitsitt F, Rao P, DeLisi L E, Virkkunen M, Linnoila M, Goldman D and Gershon E S 1994 No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia; *J. Am. Med. Assoc.* **271** 204–208
- Gibson S, Hawi Z, Straub R E, Walsh D, Kendler K S and Gill M 1999 HLA and schizophrenia; refutation of reported associations with A9 (A23/A24), DR4 and DQB1\*0602; *Am. J. Med. Genet.* **88** 416–421
- Gill M, McGuffin P, Parffit E, Mant R, Asherson P, Collier D, Vallada H, Powell J, Shaikh S, Taylor C *et al* 1993 A linkage study of schizophrenia with DNA markers from the long arm of chromosome 11; *Psychol. Med.* **23** 27–44
- Giros B, Martese M-P, Sokoloff P and Schwartz J-C 1990 Clonage du gene recepteur dopaminergique D3 humain et identification de son chromosome; *C. R. Acad. Sci. Paris* **311** 501–508
- Grandy D K, Marchionni M A, Makam H, Stofko R E, Alfano M, Frothingham L, Fischer J B, Burke-Howie K J, Bunzow J R, Server A C and Civelli O 1989 Cloning of the cDNA and gene for a human D2 dopamine receptor; *Proc. Natl. Acad. Sci. USA* **86** 9762–9766
- Grandy D K, Zhou Q Y, Allen L, Litt R, Magenis R E, Civelli O and Litt M 1990 A human D1 dopamine receptor gene is located on chromosome 5 at q35.1 and identifies an EcoRI RFLP; *Am. J. Hum. Genet.* **47** 828–834
- Gray I C, Campbell D A and Spurr N K 2000 Single nucleotide polymorphisms as tools in human genetics; *Hum. Mol. Genet.* **9** 2403–2408
- Gu C, Province M A and Rao D C 2001 Meta-analysis for model-free methods; *Adv. Genet.* **42** 255–272
- Gurling H 1998 Chromosome 21 workshop; *Psychiatr. Genet.* **8** 19–113
- Guy C A, Bowen T, Williams N, Jones I R, McCandless F, McGuffin P, Owen M J, Craddock N and O'Donovan M C 1999 No association between a polymorphic CAG repeat in

- the human potassium channel gene hKCa3 and bipolar disorder; *Am. J. Med. Genet.* **88** 57–60
- Hallmayer J, Kennedy J L, Wetterberg L, Sjogren B, Kidd K K and Cavalli Sforza L L 1992 Exclusion of linkage between the serotonin 2 receptor and schizophrenia in a large Swedish kindred; *Arch. Gen. Psychiatry* **49** 216–219
- Halushka M K, Fan J B, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R and Chakravarti A 1999 Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis; *Nat. Genet.* **2** 239–247
- Hawi Z, Mayakishev M, Straub R E, O'Neill A, Kendler K S, Walsh D and Gill M 1997 No association or linkage between the 5-HT<sub>2a</sub>/T102C polymorphism and schizophrenia in Irish families; *Am. J. Med. Genet.* **74** 370–373
- He L, Li Tao, Melville C, Liu Sheng, Feng G Y, Gu N F, Fox H, Shaw D, Breen G, Liu X, Sham P, Brown J, Collier D and St. Clair D 1999 102T/C polymorphism of serotonin receptor type 2A gene is not associated with schizophrenia in either Chinese or British populations; *Am. J. Med. Genet.* **88** 95–98
- Heath R G and Krupp I M 1967 Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody technique; *Arch. Gen. Psychiatry* **16** 1–9
- Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D and Lesch K P 1996 Allelic variation of human serotonin transporter gene expression; *J. Neurochem.* **66** 2621–2624
- Heresco-Levy U, Javitt D C, Ermilov M, Mordel C, Silpo G and Lichtenstein M 1999 Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia; *Arch. Gen. Psychiatry* **56** 29–36
- Holliday R 1989 DNA methylation and epigenetic mechanisms; *Cell Biophys.* **15** 15–20
- Holzman P S, Proctor L R and Hughes D W 1973 Eye-tracking patterns in schizophrenia; *Science* **181** 179–181
- Hovatta I, Lichtermann D, Juvonen H, Suvisaari J, Terwilliger J D, Arajarvi R, Kokko-Sahin M L, Ekelund J, Lonnqvist J and Peltonen L 1998 Linkage analysis of putative schizophrenia gene candidate regions on chromosomes 3p, 5q, 6p, 8p 20p and 22q in a population-based sampled Finnish family set; *Mol. Psychiatry* **3** 452–457
- Hranilovic D, Schwab S G, Jernej B, Knapp M, Lerer B, Albus M, Rietschel M, Kanyas K, Borrmann M, Lichtermann D, Maier W and Wildenauer D B 2000 Serotonin transporter gene and schizophrenia: evidence for association/linkage disequilibrium in families with affected siblings; *Mol. Psychiatry* **5** 91–95
- Inayama Y, Yoneda H, Ishada T, Nonomura Y, Kono Y, Koh J, Kuroda K, Higashi H, Asaba H and Sakai T 1994 An association between schizophrenia and a serotonin receptor DNA marker (5HT<sub>2</sub>); *Neuropsychopharmacology (Suppl.)* **10** 56
- Iwahashi K, Watanabe M, Nakamura K, Suwaki H, Nakaya T, Nakamura Y, Takahashi H and Ikuta K 1998 Borna disease virus infection and schizophrenia: seroprevalence in schizophrenia patients; *Can. J. Psychiatry* **43** 197
- Jain S, Leggo J, DeLisi L E, Crow T J, Margolis R L, Li S H, Gooburn S, Walsh C, Paykel E S, Ferguson-Smith M A, Ross C A and Rubinsztein D C 1996 Analysis of thirteen trinucleotide repeat loci as candidate genes for schizophrenia and bipolar affective disorder; *Am. J. Med. Genet.* **67** 139–146
- Jonsson E, Lannfelt L, Sokoloff P, Schwartz J-C and Sedvall G 1993 Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene; *Acta Psychiatr. Scand.* **87** 345–349
- Jonsson E G, Geijer T, Gyllander A, Terenius L and Sedvall G C 1998 Failure to replicate an association between a rare allele of a tyrosine hydroxylase gene microsatellite and schizophrenia; *Eur. Arch. Psychiatry Clin. Neurosci.* **248** 61–63
- Jonsson E G, Nimgaonkar V L, Zhang X R, Shaw S H, Burgert E, Crocq M A, Chakravarti A and Sedvall G C 1999 Trend for an association between schizophrenia and D3S310, a marker in proximity to the dopamine D3 receptor gene; *Am. J. Med. Genet.* **88** 352–357
- Johnson J E, Cleary J, Ahsan H, Harkavy Friedman J, Malaspina D, Cloninger C R, Faraone S V, Tsuang M T and Kaufmann C A 1997 Anticipation in schizophrenia: biology or bias? ; *Am. J. Med. Genet.* **74** 275–280
- Joober R, Benkelfat C, Brisebois K, Toulouse A, Lafreniere R G, Turecki G, Lal S, Bloom D, Labelle A, Lalonde P, Fortin D, Alda M, Palmour R and Rouleau G A 1999 Lack of association between the hSKCa3 channel gene CAG polymorphism and schizophrenia; *Am. J. Med. Genet.* **88** 154–157
- Joyce J N, Shane A, Lexow N, Winokur A, Cassanova M F and Kleinman J E 1993 Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics; *Neuropsychopharmacology* **8** 315–336
- Kaufmann C A, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel P D, Meyer J, Zambuto C T, Schmitt K, Matise T C, Harkavy Friedman J M, Hampe C, Lee H, Shore D, Wynne D, Faraone S V, Tsuang M T and Cloninger C R 1998 NIMH genetics initiative millennium schizophrenia consortium: linkage analysis of African-American pedigrees; *Am. J. Med. Genet.* **81** 282–289
- Kebabian J K and Calne D B 1979 Multiple receptors for dopamine; *Nature (London)* **277** 93–96
- Kendler K S, MacLean C J, O'Neill F A, Burke J, Murphy B, Duke F, Shinkwin R, Easter S M, Webb B T, Zhang J, Walsh D and Straub R E 1996 Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish study of high density schizophrenia families; *Am. J. Psychiatry* **153** 1534–1540
- Kennedy J L, Giuffra L A, Moises H W, Cavalli-Sforza L L, Pakstis A J, Kidd J R, Castiglione C M, Sjogren B, Wetterberg L and Kidd K K 1988 Evidence against linkage of schizophrenia to markers on chromosome 5 in a northern Swedish pedigree; *Nature (London)* **336** 167–170
- Kennedy J L and Macciardi F M 1998 Chromosome 4 workshop; *Psychiatric Genet.* **8** 67–71
- Knight J, Knight A and Ungarvi G 1992 Can autoimmune mechanisms account for the genetic predisposition for schizophrenia?; *Br. J. Psychiatry* **160** 533–540
- Knight J G 1982 Dopamine receptor stimulating autoantibody: a possible cause of schizophrenia; *Lancet* **2** 1073–1075
- Kohen R, Metcalf M A, Khan N, Druck T, Huebner K, Lachowicz J E, Meltzer H Y, Sibley D R, Roth B L and Hamblin M W 1996 Cloning, characterization and chromosomal localization of a human 5-HT<sub>6</sub> serotonin receptor; *J. Neurochem.* **66** 47–56
- Kojima H, Ohmori O, Shinkai T, Terao T, Suzuki T and Abe K 1999 Dopamine D1 receptor gene polymorphism and schizophrenia in Japan; *Am. J. Med. Genet.* **88** 116–119
- Kouzman A P, Scaffidi A, Pereira A M, Hayes W L, Copolov D L and Dean B 1999 No correlation between A(-1438)G polymorphism in 5HT<sub>2A</sub> receptor gene promoter and the density of frontal cortical 5HT<sub>2A</sub> receptors in schizophrenia; *Hum. Hered.* **49** 103–105

- Lechler R 1994 *HLA and diseases* (London: Academic Press)
- Levy D L, Holzman P S, Matthyse S, Mendell N R 1993 Eye tracking dysfunction and schizophrenia: a critical perspective; *Schizophr. Bull.* **19** 461–536
- Lin C H, Tsai S J, Yu Y W, Song H L, Tu P C, Sim C B, Hsu C P, Yang K H and Hong C J 1999 No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population; *Neuroreport* **10** 57–60
- Litt M, Al-Dhalimy M, Zhou Q, Grandy D and Civelli O 1991 A TaqI RFLP at the DRD1 locus; *Nucleic Acids Res.* **19** 3161
- Liu Q, Janet L S, Leonard L H, Steve S S 1995 Screening the dopamine D1 receptor gene in 131 schizophrenics and eight alcoholics; *Am. J. Med. Genet.* **60** 165–171
- Maier W, Schmidt F, Schwab S G, Hallmeyer J, Minges J, Ackenheil M, Lichtermann D and Wildenauer D B 1995 Lack of linkage between schizophrenia and markers at the telomeric end of the pseudoautosomal region of the sex chromosome; *Biol. Psychiatry* **37** 344–347
- Mant R, Williams J, Asherson P, Parfitt E, McGuffin P and Owen M J 1994 Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia; *Am. J. Med. Genet.* **54** 21–26
- Matsumoto M and Yoshioka M 2000 Possible involvement of serotonin receptors in anxiety disorders; *Nippon Yakurigaku Zasshi* **115** 39–44
- Maziade M, Debraekeleer M, Genest P, Cliché D, Fournier J P, Garneau Y, Shriqui C, Roy M A, Nicole L, Raymond V *et al* 1993 A balanced 2:18 translocation and familial schizophrenia: falling short of an association; *Arch. Gen. Psychiatry* **50** 73–75
- McGuffin P, Owen M J and Farmer A E 1995 The genetic basis of schizophrenia; *Lancet* **346** 678–682
- McGuffin P, Sargeant M, Hetti G, Tidmarsh S, Whatley S and Marchbanks R M 1990 Exclusion of a schizophrenia susceptibility gene from the chromosome 5q11-13 region: new data and a reanalysis of previous reports; *Am. J. Hum. Genet.* **47** 524–535
- McInnis M, Lee P, Ginnis E I, Lenane M, Kumra S, Jacobsen L, Rapport J L and Schalling M 1998 Large CAG/CTG repeats are associated with childhood-onset schizophrenia; *Mol. Psychiatry* **3** 321–327
- McInnis M G 1996 Anticipation: an old idea in new genes; *Am. J. Hum. Genet.* **59** 973–979
- Meloni R, Leboyer M, Bellivier F, Barbe B, Samolyk D, Allilaire J F and Mallet J 1995 Association of manic depressive illness with the TH locus using a microsatellite marker localized in the tyrosine hydroxylase gene; *Lancet* **345** 932
- Meszáros K, Lenzinger E, Fureder T, Hornik K, Willinger U, Stompe T, Heiden A M, Resinger E, Fathi N, Gerhard E, Fuchs K, Miller-Reiter E, Pfersmann V, Sieghart W, Aschauer H N and Kasper S 1996 Schizophrenia and the dopamine-beta hydroxylase gene: results of a linkage and association study; *Psychiatric Genet.* **6** 17–22
- Mignot E, Kimura A, Abbal M, Thorsby E, Lin X, Voros A, Macaubas C, Bouissou F, Sollid L M, Thomsen A C, Yasunaga S and Grumet F C 1995 DQCAR microsatellite polymorphisms in three selected HLA class II-associated diseases; *Tissue Antigens* **46** 299–304
- Moises H W, Yang L, Kristbjarmarson H, Weise C, Byerley W, Macciardi F, Arolt V, Blackwood D, Liu X, Sjogren B, Aschauer H N, Hwu H G, Jang K, Livesley W J, Kennedy J L, Zoega T, Ivarsson O, Bui M T, Yu M H, Havesteen B, Commenges D, Weissenbach J, Schwinger E, Gottesman II, Pakstis A J, Wetterberg L, Kidd K K and Helgason T 1995 An international two-stage genome wide search for schizophrenia susceptibility genes; *Nature Genet.* **11** 233–234
- Morris A G, Gaitonde E J, McKenna P J, Mollon J D and Hunt D M 1995 CAG repeat expansions and schizophrenia: association with disease in females and with early age-at-onset; *Hum. Mol. Genet.* **4** 1957–1961
- Muller N, Ackenheil M, Hofschuster E, Mempel W and Eckstein R 1991 Cellular immunity in schizophrenic patients before and during neuroleptic treatment; *Psychiatry Res.* **37** 147–160
- Murphy K C, Jones R G, Griffiths E, Thompson P W and Owen M J 1998 Chromosome 22q11 deletions. An under-recognized cause of idiopathic learning disability; *Br. J. Psychiatry* **17** 180–183
- Nakatome M, Honda K, Tun Z, Kato Y, Harihara S, Omoto K, Misawa S, Gerelsaikhhan T, Nyamkhisig S, Dashnyam B, Batsuuri J and Wakasugi C 1996 Genetic polymorphism of the 3' VNTR region of the human dopaminergic function gene DAT1 (Human Dopamine Transporter Gene) in the Mongolian population; *Hum. Biol.* **68** 509–515
- Nanko S, Hattori M, Dai X Y, Fukuda R and Kazamatsuri H 1994 DRD2 Ser311/Cys311 polymorphism in schizophrenia; *Lancet* **343** 1044–1045
- Nanko S, Sasaki T, Fukuda R, Hattori M, Dai X Y, Kazamatsuri H, Kuwata S, Juji T and Gill M 1993 A study of association between schizophrenia and dopamine D3 receptor gene; *Hum. Genet.* **92** 336–338
- Naylor L, Dean B, Pereira A, Mackinnon A, Kouzmenko A and Copolov D 1998 No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus; *Mol. Med.* **4** 671–674
- Nimgaonkar V L, Ganguli R, Rudert W A, Vavassori C, Rabin B S and Trucco M 1992 A negative association of schizophrenia with an allele of the HLA DQB1 gene among African-Americans; *Am. J. Med. Genet.* **81** 199–209
- Nimgaonkar V L, Rudert W A, Zhang X R, Trucco M and Ganguli R 1997 Negative association of schizophrenia with HLADQB1\*0602: evidence from a second African-American cohort; *Schizophr. Res.* **23** 81–86
- Nimgaonkar V L, Rudert W A, Zhang X R, Tsoi W F, Trucco M and Saha N 1995 Further evidence for an association between schizophrenia and the HLADQB1 gene locus; *Schizophr. Res.* **18** 43–49
- Nimgaonkar V L, Zhang X R, Caldwell J G, Ganguli R and Chakravarti A 1993 Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: Probable effects of family history; *Am. J. Med. Genet.* **48** 214–217
- Nimgaonkar V L, Zhang X R, Brar J S, DeLeo M and Ganguli R 1996 5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected; *Psychiatr. Genet.* **6** 23–27
- Nöthen M M, Erdmann J, Shimron-Abarbanell D and Propping P 1994 Identification of genetic variation in the human serotonin1D $\beta$  receptor gene; *Biochem. Biophys. Commun.* **205** 1194–1200
- Nöthen M M, Korner J, Lannfelt L, Sokoloff P, Schwartz J-C, Lanczik M, Rietschel M, Cichon S, Kramer R, Fimmers R, Möller H-J, Beckmann H, Propping P, Grandy D K, Civelli O and O'Dowd B F 1993a Lack of association between schizophrenia and alleles of the dopamine D1, D2, D3 and D4 receptor loci; *Psychiatr. Genet.* **3** 89–94
- Nöthen M M, Cichon S, Propping P, Fimmers R, Schwab S G and Wildenauer DB 1993b Excess of homozygosity at the

- dopamine D3 receptor gene in schizophrenia not confirmed; *J. Med. Genet.* **30** 708
- O'Donovan M C, Guy C, Craddock N, Murphy K C, Cardno A G, Jones L A, Owen M J and McGuffin P 1995 Expanded CAG repeats in schizophrenia and bipolar disorder; *Nature Genet.* **6** 14–18
- Oliveira M J R, Otto P A, Vallada H, Lauriano V, Elkis H, Lafer B, Vasquez L, Gentil V, Passos-Bueno M R and Zatz M 1998 Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia; *Am. J. Med. Genet.* **81** 225–227
- O'Reilly R L and Singh S M 1996 Retroviruses and schizophrenia revisited; *Am. J. Med. Genet.* **67** 19–24
- Parfitt E, Asherson P, Roberts E, Mant R, Nanko S, Gill M, McGuffin P and Owen M 1996 No evidence for linkage between schizophrenia and eight microsatellite markers on chromosome 19; *Hum. Hered.* **46** 191–196
- Peau B S, Laurent C, Campion D, Jay M, Thibaut F, Dollfus S, Petit M, Samolyk D, d'Amato T, Martinez M and Mallet J 1995 No evidence for linkage or association between the dopamine transporter gene and schizophrenia in a French population; *Psychiatr. Res.* **59** 1–6
- Perisco A M and Macciardi F 1997 Genotypic association between dopamine transporter gene polymorphisms and schizophrenia; *Am. J. Med. Genet.* **74** 53–57
- Perisco A M, Vandenberg D J, Smith S S and Uhl G R 1993 Dopamine transporter gene markers are not associated with polysubstance abuse; *Biol. Psychiatry* **34** 265–267
- Perisco A M, Wang Z W, Black D W, Andreasen N C, Uhl G R and Crowe R R 1995 Exclusion of close linkage of the dopamine transporter gene with schizophrenia spectrum disorders; *Am. J. Psychiatr.* **152** 134–136
- Petronis A 2000 The genes for major psychosis: aberrant sequence or regulation?; *Neuropsychopharmacology* **23** 1–11
- Petronis A, Paterson A D and Kennedy J L 1999 Schizophrenia: An Epigenetic Puzzle; *Schizophr. Bull.* **25** 639–655
- Prasad S, Deshpande S, Bhatia T, Wood J, Nimgaonkar V L and Thelma B K 1999 An association study of schizophrenia among Indian families; *Am. J. Med. Genet.* **88** 298–300
- Pulver A E, Lasseter V K, Kasch L, Wolyniec P S, Nestadt G, Blouin J L, Kimberland M, Babb R, Vourlis S, Chen H, Lalioti M, Morris M A, Karayiorgou M, Ott J, Meyers D, Antonarakis S, Housman D and Kazaazian H H 1995 Schizophrenia: a genome scan targets chromosome 3p and 8p as potential sites of susceptibility genes; *Am. J. Med. Genet.* **60** 252–260
- Pulver A E, Nestadt G, Goldberg R, Shprintzen R J, Lamacz M, Wolyniec P S, Morrow B, Karayiorgou M, Antonarakis S E, Housman D and Kucherlapati R 1994 Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives; *J. Nerv. Ment. Dis.* **182** 476–478
- Rao D, Jonsson E G, Pauss S, Ganguli R, Nothen M and Nimgaonkar V L 1998 Schizophrenia and the serotonin transporter gene; *Psychiatr. Genet.* **8** 207–212
- Riley B P, Lin M W, Mogudi-Carter M, Jenkins T, Williamson R, Powell J F, Collier D and Murray R 1998 Failure to exclude a possible schizophrenia susceptibility locus on chromosome 13q14.1-q32 in southern African Bantu speaking families; *Psychiatr. Genet.* **8** 155–162
- Riley B P and McGuffin P 2000 Linkage and associated studies of schizophrenia; *Am. J. Med. Genet. (Semin. Med. Genet.)* **97** 23–44
- Riley B P, Tahir E, Rajagopalan S, Mogudi-Carter M, Faure S, Weissenbach J, Jenkins T and Williamson R 1997 A linkage study of the N-Methyl-D-aspartate receptor subunit gene loci and schizophrenia in southern African-Bantu speaking families; *Psychiatric. Genet.* **7** 57–74
- Risch N 1990 Linkage strategies for genetically complex traits. I. Multilocus models; *Am. J. Hum. Genet.* **46** 222–228
- Ross C A, McInnis M G, Margolis R I and Li S-H 1993 Genes with triplet repeats: Candidate mediators of neuropsychiatric disorders; *Trends. Neurosci.* **16** 254–260
- Rotando A, Schuebel K, Bergen A, Aragon R, Virkkunen M, Linnoila M, Goldman D and Nielsen D 1999 Identification of four variants in the tryptophan hydroxylase promoter and association to behaviour; *Mol. Psychiatry* **4** 360–368
- Rubinsztein D C, Leggo J, Goodburn S, Crow T J, Lofthouse R, DeLisi L E, Barton D E and Ferguson-Smith M A 1994 Study of the Huntington's disease (HD) gene CAG repeats in schizophrenic patients shows overlap of the normal and HD affected ranges but absence of correlation with schizophrenia; *J. Med. Genet.* **31** 690–693
- Saleem Q, Ganesh S, Vijaykumar M, Reddy Y C J, Brahmachari S K and Jain S 2000a Association analysis of 5HT transporter gene in bipolar disorder in the Indian population; *Am. J. Med. Genet.* **96** 170–172
- Saleem Q, Sreevidya V S, Sudhir J, Savithri J V, Gowda Y, Rao C B, Benegal V, Majumdar P P, Anand A, Brahmachari S K and Jain S 2000b Association analysis of CAG repeats at KCNN3 locus Indian patients with bipolar disorder and schizophrenia; *Am. J. Med. Genet.* **96** 744–748
- Saleem Q, Vijaykumar M, Mutsuddi M, Chowdhary N, Jain S and Brahmachari S K 1998 Variation at the MJD locus in the major psychoses; *Am. J. Med. Genet.* **81** 440–442
- Schmauss C, Haroutunian V, Davis K L and Davidson M 1993 Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia; *Proc. Natl. Acad. Sci. USA* **90** 8942–8946
- Schwab S G, Albus M, Hallmeyer J, Honig S, Borrmann M, Lichtermann D, Ebstein R P, Ackenheil M, Lerer B, Risch N, Maier W and Wildenauer D B 1995 Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis; *Nature Genet.* **11** 325–327
- Schwab S G, Hallmeyer J, Albus M, Lerer B, Hanses C, Kanyas K, Segman R, Borrmann M, Dreikorn B, Lichtermann D, Rietschel M, Trixler M, Maier W and Wildenauer D B 1998 Further evidence for a susceptibility locus on chromosome 10p14-p11 in 72 families with schizophrenia by non-parametric linkage analysis; *Am. J. Med. Genet.* **81** 302–307
- Schwab S G, Hallmeyer J, Lerer B, Albus M, Borrmann M, Honig S, Strauss M, Segman R, Lichtermann D, Knapp M, Trixler M, Maier W and Wildenauer D B 1998 Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis; *Am. J. Hum. Genet.* **63** 1139–1152
- Sedvall G and Farde L 1995 Chemical brain anatomy in schizophrenia; *Lancet* **346** 743–749
- Semwal P, Prasad S, Bhatia T, Deshpande S N, Wood J, Nimgaonkar V L and Thelma B K 2001 Family based studies of monoaminergic gene polymorphism among Indians with schizophrenia; *Mol. Psychiatry* **6** 220–224
- Serreti S A, Lilli R, Lorenzi C, Lattuada E, Cusin C and Smeraldi E 1999 Lack of association between tryptophan hydroxylase gene and psychotic symptomatology in schizophrenia; *Schizophr. Res.* **40** 171–172

- Shaw S H, Kelly M, Smith A B, Shields G, Hopkins P J, Loftus J, Laval S H, Vita A, De Hert M, Cardon L R, Crow T J, Sherrington R and DeLisi L E 1998 A genome-scan search for schizophrenia susceptibility genes; *Am. J. Med. Genet.* **81** 364–376
- Shaikh S, Collier D, Arranz M, Ball D, Gill M and Kerwin R 1994 DRD2 Ser311/Cys311 polymorphism in schizophrenia; *Lancet* **343** 1045–1046
- Sherrington R, Brynjolfsson J, Petursson H, Potter M, Dudleston K, Barraclough B, Wasmuth J, Dobbs M and Gurlin H 1988 Localization of a susceptibility locus for schizophrenia on chromosome 5; *Nature (London)* **336** 164–167
- Shima S, Yano K, Sagiura M and Tokunaga Y 1991 Anti-cerebral antibodies in functional psychoses; *Biol. Psychiatry* **29** 322–328
- Shinkai T, Ohmori O, Kojima H, Terao T, Suzuki T and Abe K 1999 Association study of the 5-HT<sub>6</sub> receptor gene in schizophrenia; *Am. J. Med. Genet.* **88** 120–122
- Sidenberg D G, Basset A S, Demchyshyn L, Niznik H B, Macciardi F, Kamble A B, Honer W G and Kennedy J L 1993 New polymorphism for the human serotonin 1D receptor variant (5HTID) beta linked to schizophrenia in five Canadian pedigrees; *Hum. Hered.* **43** 315–318
- Silvermann J M, Greenberg D A, Altsteil L D, Siever L J, Mohs R C, Smith C J, Zhou G, Hollander T E, Yang X P, Kedache M, Li G, Zaccario M L and Davis K L 1996 Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree; *Am. J. Med. Genet.* **67** 162–171
- Sobell J, Sigurdson D C, Heston L and Sommer S 1994 S311C D2DR variant: No association with schizophrenia; *Lancet* **344** 621–622
- Solomon G F 1981 Immunologic abnormalities in mental illness; in *Psychoneuroimmunology* (ed.) R Ader (New York: Academic Press)
- Sommer S S, Lind T J, Heston L L and Sobell J L 1993 Dopamine D4 receptor variants in unrelated schizophrenic cases and controls; *Am. J. Med. Genet.* **48** 90–93
- Spurlock G, Heils A, Holmans P, Williams J, D'Souza U M, Cardno A, Murphy K C, Jones L, Buckland P R, McGuffin P, Lesch K P and Owen M J 1998 A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter; *Mol. Psychiatry* **3** 42–49
- Stahl S M and Wets K 1987 Indoleamines and schizophrenia; in *Neurochemistry and neuropharmacology of schizophrenia* (Amsterdam: Elsevier) pp 257–296
- St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G, Gosden C and Evans H J 1990 Association within a family of a balanced autosomal translocation with major mental illness; *Lancet* **336** 13–16
- Straub R E, MacLean C J, O'Neill F A, 1997 Support for a possible schizophrenia vulnerability locus in region 5q22-31 in Irish families; *Mol. Psychiatry* **2** 148–155
- Straub R E, MacLean C J, O'Neil F A, Burke J, Murphy B, Duke F, Shinkwin R, Webb B T, Zhang J, Walsh D and Kendler K S 1995 A potential vulnerability locus for schizophrenia on chromosome 6p24-22: Evidence for genetic heterogeneity; *Nature Genet.* **11** 287–293
- Sunhara R K, Guan H-C and O'Dowd B F, Seeman P, Laurier L G, Ng G, George S R, Torchia J, Van Tol H H and Niznik H B 1991 Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1; *Nature (London)* **350** 614–619
- Thomson G 2001 An overview of the genetic analysis of complex diseases, with reference to type I diabetes; *Best Pract. Res. Clin. Endocrinol. Metab.* **15** 265–277
- Thomson G, Robinson W, Kuhner M, Joe S and Klitz W 1989 HLA and insulin gene associations with IDDM; *Genet. Epidemiol.* **6** 155–160
- Thomson R 1996 *The brain: A neuroscience primer* Second edition (New York: W H Freeman)
- Toyooka K, Murataka T, Tanaka T, Igarashi S, Watanabe H, Takeuchi H, Hayashi S, Maeda M, Takahashi M, Tsuji S, Kumanishi T and Takahashi Y 1999 14-3-3 protein eta chain gene (YWHAH) polymorphism and its genetic association with schizophrenia; *Am. J. Med. Genet.* **88** 164–167
- Trucco M 1992 To be or not to be Asp57, that is the question; *Diabetes Care* **15** 705–715
- Tsai G, van Kammen D P, Chen S, Kelley M E, Grier A and Coyle J T 1998 Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia; *Biol. Psychiatry* **44** 667–674
- Vandenberg D J, Perisco A M, Hawkins A L, Griffin C A, Li X, Jabs E W and Uhl G R 1992a Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR; *Genomics* **14** 1104–1106
- Vandenberg D J, Perisco A M and Uhl G R 1992b A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially dimorphic Taq I RFLPs; *Mol. Brain Res.* **15** 161–166
- Van Tol H H M, Bunzow J R, Guan H-C, 1991 Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine; *Nature (London)* **350** 610–614
- Verga M, Macciardi F, Cohen S, Pedrini S and Smeraldi E 1997 No association between schizophrenia and the serotonin receptor 5HTR2a in an Italian population; *Am. J. Med. Genet.* **74** 21–25
- Warren J T, Peacock M L, Rodoriguez L C and Fink J K 1993 An MspI polymorphism in the human serotonin receptor gene (HTR2): Detection by DGE and RFLP analysis; *Hum. Mol. Genet.* **2** 338
- Wei J and Hemmings P G 2000 The NOTCH4 locus is associated with susceptibility to schizophrenia; *Nature Genet.* **25** 376–377
- Williams J, McGuffin P, Nothen M and Owen M J 1997 Meta-analysis of association between the 5-HT<sub>2a</sub> receptor T102C polymorphism and schizophrenia; *Lancet* **349** 1221
- Williams J, Spurlock G, McGuffin P, Mallet J, Nothen M M, Gill M, Aschauer H, Nylander P O, Macciardi F and Owen M J 1996 Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a receptor gene; *Lancet* **347** 1294–1296
- Williams N M, Rees M I, Holmans P, Norton N, Cardno A G, Jones L A, Murphy K C, Sanders R D, McCarthy G, Gray M Y, Fenton I, McGuffin P and Owen M J 1999 A two-stage genome scan for schizophrenia susceptibility genes in 196 affected sibling pairs; *Hum. Mol. Genet.* **8** 1729–1739
- Wittekindt O, Jauch A, Burgert E, Scharer L, Holtgreve-Grez H, Yvert G, Imbert G, Zimmer J, Hoehe M R, Macher J P, Chiaroni P, van Calker D, Crocq M A and Morris-Rosendahl D J 1998 The human small conductance calcium-regulated potassium channel gene (hSKCa3) contains two CAG repeats in exon 1, is on chromosome 1q21.3, and shows a possible association with schizophrenia; *Neurogenetics* **1** 259–265

- Wright P, Donaldson P T, Underhill J A, Choudhuri K, Doherty D G and Murray R M 1996 Genetic association of the HLADRB1 gene locus on chromosome 6p21.3 with schizophrenia; *Am. J. Psychiatry* **153** 1530–1533
- Yamada K, Nanko S, Hattori S and Isurugi K 1982 Cytogenetic studies in a Y-to-X translocation observed in three members of one family, with evidence of infertility in male carriers; *Hum. Genet.* **60** 85–90
- Yolken R H, Karlsson H, Yee F, Johnston-Wilson N L and Torrey E F 2000 Endogenous retroviruses and schizophrenia; *Brain Res. Rev.* **31** 193–199
- Zamani M G, De Hert M, Spaepen M, Hermans M, Marynen P, Cassiman J J and Peuskens J 1994 Study of the possible association of HLA class II, CD4, and CD3 polymorphisms with schizophrenia; *Am. J. Med. Genet.* **54** 372–377